The U.S. Dupixent market, valued at USD 11.04 billion in 2024, is expected to grow at a CAGR of 5.7% from 2025 to 2034, reflecting the drug’s entrenched position in the global biologics market and its strategic importance to leading pharmaceutical companies. The U.S. remains the largest revenue contributor, driven by high patient demand, robust reimbursement frameworks, and a favorable...